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The objective of this study was to develop an in vitroein vivo correlation (IVIVC) model for
hydrophilic matrix extended-release (ER) propranolol dosage formulations. The in vitro
release characteristics of the drug were determined using USP apparatus I at 100 rpm, in a
medium of varying pH (from pH 1.2 to pH 6.8). In vivo plasma concentrations and phar-
macokinetic parameters in male beagle dogs were obtained after administering oral, ER
formulations and immediate-release (IR) commercial products. The similarity factor f2 was
used to compare the dissolution data. The IVIVC model was developed using pooled
fraction dissolved and fraction absorbed of propranolol ER formulations, ER-F and ER-S,
with different release rates. An additional formulation ER-V, with a different release rate
of propranolol, was prepared for evaluating the external predictability. The results showed
that the percentage prediction error (%PE) values of Cmax and AUC0eN were 0.86% and
5.95%, respectively, for the external validation study. The observed low prediction errors
for Cmax and AUC0eN demonstrated that the propranolol IVIVC model was valid.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license. 1. Introduction considerable amount of time and money. Thus, the applica-In vitroein vivo correlation (IVIVC) plays a key role in the
pharmaceutical development of dosage forms. IVIVC can
serve as a surrogate for in vivo bioavailability and to support
biowaivers. It also allows setting of the dissolution specifica-
tion and methods [1,2]. In order to prove the validity of a new
formulation, a bioequivalence study may be needed, taking a, Taipei Medical Universi
, Kaohsiung Medical Uni
P.-C. Wu), kyhsu@tmu.ed
ministration, Taiwan. Publition of IVIVC attracts the attention of the pharmaceutical
industry.
Development and validation are two critical stages in the
evaluation of an IVIVC model. In the first stage, the develop-
ment of a level A IVIVC model is usually estimated by a two-
stage process [1]. At the first stage, the observed fraction of
the drug absorbed is estimated using the numericalty, Taiwan, ROC.
versity, Taiwan, ROC.
u.tw (K.-Y. Hsu).
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using the observed fraction of the drug absorbed and that of
the drug dissolved. Based on the IVIVC model, the predicted
fraction of the drug absorbed is calculated from the observed
fraction of the drug dissolved. The predicted fraction of the
drug absorbed is then convolved to the predicted plasma
concentrations by using the convolution method. In the sec-
ond stage, the predictability evaluation of the IVIVC model
should focus on estimating the percent prediction error (%PE)
between the observed and predicted plasma concentration
profiles, such as the difference in pharmacokinetic parame-
ters [Cmax and the area under the curve from time zero to in-
finity (AUC0eN)]. The internal and/or external evaluation of
the %PEmay also be appropriate. The internal predictability is
based on the initial data used to define the IVIVC model, and
the external predictability is based on the additional data [1].
Propranolol is a non-selective beta adrenergic blocking
agent and is widely used for the treatment of angina pectoris,
hypertension, and many other cardiovascular disorders. After
oral administration, propranolol is almost completely absor-
bed. However, the bioavailability of propranolol is extremely
limited (30%), due to the hepatic first-pass effect, and its elim-
ination half-life is also relatively short (approximately 2e6
hours) [3]. For hypertension treatment, the usual dose is
120e240mgdivided in 2e3 doses/day; themaximumdaily dose
is 640 mg. Therefore, propranolol was a good candidate for the
preparation of the once-daily extended-release (ER) dosage
formulation. Many IVIVC studies have been reported regarding
controlled-release formulations [4e10], but there are none
regarding propranolol matrix ER formulations. Thus, devel-
oping an IVIVC model of propranolol ER tablets is beneficial for
obtaining biowaivers for scale-up and certain pre- or post-
approval changes. The objective of this studywas to develop an
IVIVC model for propranolol ER dosage formulations. The
validation of the internal and external predictabilities was
completed for a wide range of formulations. In addition, IVIVC
of the drug in the animal models provides the feasibility of the
drug delivery system for a given drug candidate. The objective
of this study was to use propranolol as a model drug, using
hydroxypropyl methylcellulose (HPMC), Avicel, and lactose to
develop formulations with different release rates, and also to
set up the IVIVC animal model to evaluate the feasibility of the
drug delivery system. Such an approach may also be applied to
the development of other drug candidates in the future.Table 1 e Propranolol extended-release tablets used in
the development and validations of in vitroein vivo
correlation IVIVC.
Formulations
ER-F ER-S ER-V
BioStudy Internal Internal External
Ingredients (%) of tablets
HPMC 28.0 60.0 38.4
Avicel 26.2 15.0 5.8
Lactose 20.8 0.0 27.3
Each tablet contains propranolol 100 mg.
HPMC ¼ hydroxypropyl methylcellulose.2. Methods
2.1. Materials and equipment
Propranolol hydrochloride and p-hydroxybenzoate-butyl
ester were purchased from TCI Co. (Tokyo, Japan), hydrox-
ypropyl methylcellulose (HPMC) was from Shin Etsu, (Tokyo,
Japan), microcrystalline cellulose (Avicel) was from Asahi Co.
(Tokyo, Japan), and lactose was from New Zealand Lactose Co
(Hawera, New Zealand). All chemicals and solvents used were
of analytical reagent grade.
Six Beagles dogs used in this study were supplied from the
animal center of National Pingtung University of Science andTechnology (NPUST) (Pingtung, Taiwan). Each adult beagle
dog weighed between 8 and 14 kg.
2.2. Formulations
ER tablets of propranolol hydrochloride formulated using
HPMC, Avicel, and lactose formodifying the release rates have
been discussed previously [11]. Two ER tablets were designed
to release propranolol at two different rates referred to as:
slow (ER-S) and fast (ER-F) for the development of the IVIVC
model. The compositions of these ER tablets are shown in
Table 1. For evaluating the external predictability of the IVIVC
model, an additional formulation, ER-V, with a release rate
between those of formulation ER-S and ER-F, was prepared; it
underwent dissolution test and in vivo absorption studies.
2.3. Dissolution test
The release characteristics of the propranolol ER tablets were
determined using USP apparatus I, the basket method. The
rotation speed was set at 100 rpm. The propranolol tablets
were placed in 900 mL of gastric fluid and maintained at 37C.
Samples (5mL)were collected, each at an appropriate interval.
After 1.5 hours, the pH of the dissolution medium was varied
from 1.2 to 6.8 by adding 80 mL of concentrated phosphate
buffer to simulate the intestinal fluid, and then the experi-
ment was run for the specified time. The dissolution samples
were collected at the following time intervals: 0, 0.5, 1, 1.5, 2, 3,
4, 5, 6, 8, 10, 12, and 24 hours. The amount of drug releasedwas
analyzed by ultraviolet/visible spectrophotometry at 290 nm
wavelength. At least six tablets of each formulation were
accomplished. The mean and standard deviation (SD) of dis-
solved percentages were calculated.
2.4. In vivo absorption studies
The animal experimental protocol was approved by the
Institutional Animal Care and Use Committee of Kaohsiung
Medical University. The committee confirmed that the animal
experiment had followed the guidelines as set forth by the
Guide for Laboratory Fact lines and Care. All of the dogs were
fasted 12 hours prior to the experiment, but water drinking
was not limited. Their legs were pre-shaved, and a forefoot
vein was cannulated using an 18-gauge cannula. Blood sam-
ples (3 mL) were collected in a heparin tube at the
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hours, after administering the experimental ER tablets
(100 mg) and commercial immediate-release (IR) tablets
(40 mg, Astrazeneca, London, UK) orally. Each treatment was
separated by a washout period of at least 1 week. The blood
samples were centrifuged at 3000 rpm for 10 minutes, and the
plasma was taken and kept frozen for further analysis. The
plasma drug concentration was determined according to a
previous method [12]. A Merck (Darmstadt, Germany) Lichro-
cart C18 column (250 4mm I.D., particle size 5 mm)was used.
The mobile phase was a mixture of acetonitrile and a pH 3.0
acetic acid aqueous solution at ratio of 25:75, at a flow rate of
1mL/minute. The detectionwavelengthwas set to 230 nmand
the excitation wavelength to 340 nm. The concentration,
ranging from 5 ng/mL to 1000 ng/mL, showed a linearity
(r ¼ 0.996). The coefficients of variation (CV%, n ¼ 6) ranged
from 0.64% to 17.82% for the interday and intraday analyses.
The lower limit of quantitation was 5 ng/mL.
2.5. In vitro data analysis
Dissolution analyses for each tablet were conducted by plot-
ting the cumulative percentage of the propranolol dissolved at
different time points. The in vitro drug release profiles of the ER
formulations were compared using the similarity factor f2 [13].
An f2 value >50 (50e100) represents similarity or equivalence
of the two curves.
2.6. In vivo data analysis
The pharmacokinetic parameters of the reference product for
developing the IVIVC, namely, the volume of distribution (Vd)
and elimination rate constant (Ke), were obtained from the IR
product by fitting a one-compartment model using WIN-
NONLIN software (Pharsight Corporation, Mountain view, CA,
USA). Then, the numerical deconvolution analysis provided
by WINNONLIN was used to acquire % in vivo cumulative ab-
sorption input profiles of propranolol from the ER tablets. A
mathematical model (IVIVC Mode), which related the in vitro
cumulative dissolution data release to the fraction of drug
absorbed, was developed by linear regression. The relation-
ship of in vitro cumulative dissolution data and in vivo cumu-
lative absorption data is shown in Eq. 1.% in vivo cumulative input ðtÞ ¼ a þ b  % in vitro cumulative dissolved ðtÞ (1)where the data for “% in vivo cumulative input (t)” was ob-
tained from the numerical deconvolution approach and “%
in vitro cumulative dissolved (t)” from the experimental data.
The intercept, slope, and determination coefficient of the
regression line are denoted by a, b, and r2, respectively.2.7. Evaluation of the IVIVC model
The validation of the IVIVC model can be accomplished by
using the internal and/or external predictabilities. The internal
predictability involves the use of the initial data used to define
the IVIVC model. Hence, the predicted plasma concentrationprofiles of formulation ER-S and ER-F were calculated using
their in vitrodissolutiondata. For the external predictability, an
additional formulation ER-V with an in vitromoderate release
rate between formulation ER-S and formulation ER-F was
prepared. The in vitro dissolution test and bioavailability study
of formulation ER-V were conducted. The predicted plasma
concentration profile of formulation ER-V was calculated by
using its dissolution data based on the IVIVC model.
The “predicted % in vivo cumulative input (t)” data were
calculated using the intercept, slope, and “% in vitro cumula-
tive dissolved (t)” data. In other words, the “% in vivo cumu-
lative input (t) data” versus time profile was estimated from
the “% in vitro cumulative dissolved (t) data” based on an
established IVIVC model. Subsequently, the predicted in vivo
input rates for the ER formulation were obtained from the “%
in vivo cumulative input (t) data” as shown in Eq. 2.
Rinput ¼

% in vivo input ðt2
 % in vivo input ðt1t2  t1
 dose
(2)
where “R input” is the “predicted in vivo input rates” and “%
in vivo input (t)” is the input value at the time point t.
Then, according to Eq. 3, the unit disposition function [14],
“the predicted in vivo input rates” was converted to the pre-
dicted plasma concentration-time profiles using Microsoft
Excel 2010 (Microsoft corporation, Washington, USA).
CpðtÞ ¼
Xm
t¼1

Rj
l

elðts2Þ  elðts1Þ
	
(3)
where Cp(t) is the predicted plasma concentration at time
point t; Rj is the j-th input rate; s1 is the start time of the j-th
input rate; and s2 is the stop time of the j-th input rate. In
addition, the unit deposition function parameters were ob-
tained by fitting a one-compartment model to the IR formu-
lation plasma concentration-time profile. C and l were
calculated as the reciprocal of Vd and Ke, respectively, for a
one-compartment model (mono exponential).
The absolute percent prediction error (%PE) values for Cmax
and AUC0eN are calculated as follows:
%PE ¼ Pobs  Ppred
Pobs
(4)wherePobsandPpredaretheobservedandIVIVCmodel-predicted
values for Cmax and AUC0eN, respectively. The IVIVC is
considered valid if the averaged absolute %PE is not more than
10% and if the %PE for each formulation is not more than 15%.3. Results and discussion
3.1. In vitro studies
The mean dissolution profiles of propranolol ER tablets ER-F
and ER-S are shown in Fig. 1A. The calculated similarity
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Fig. 2 e Mean propranolol plasma concentrations versus
time profiles of formulation (A) extended-release tablets of
ER-F (:) and ER-S (-); (B) immediate-release commercial
products (IR) (A).
Table 2 e Mean pharmacokinetic parameters of
propranolol extended-release (ER) tablets and
immediate-release (IR) commercial product.
Formulations Cmax (ng/mL) Tmax (h) AUC0eN
(ng  h/mL)
ER-F 140.82  23.85 1.88  1.44 1059.12  128.90
ER-S 78.83  31.42 1.50  0.41 955.35  159.89
IR 347.33  9.28 0.50  0.00 758.06  199.19
AUC0eN ¼ area under the curve form time zero to infinity;
Cmax ¼ maximum observed plasma propranolol concentration;
Tmax ¼ time to Cmax.
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value of f2 was <50, indicating dissimilarity between the
curves. The wide variation indicated that the combinations
component of formulation (Table 1) resulted in different drug
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Fig. 3 e Mean cumulative percentage absorption rate of
propranolol of extended-release formulations ER-F (:) and
ER-S (-) calculated by using the numerical deconvolution
approach.
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Fig. 5 e Mean observed (symbols) and predicted (solid line) propranolol plasma concentrations versus time profiles of
extended-release formulations ER-F (:) and ER-S (-) and ER-V (B). Error bars displayed standard deviations of observed
data.
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the in vitro dissolution profile shown in Fig. 1, the release rate
of ER-S was much slower than those of other formulations. In
the ER-S formulation, there is no lactose added. Based on a
previous study by Huang et al [11], lactose incorporated into
the gel-forming matrix could improve the phenomenon in
in vitro and/or in vivo studies, because these excipients could
stimulate the water penetration into the inner parts of the
matrix, thus resulting in the drug release from thematrix. Thelactose inside the matrix would dissolve and became porous
and the dissolution rate was increased.
For the external validation study, an additional propranolol
ER formulation ER-V, with a different release rate from ER-F
and ER-S, was prepared and subjected to a dissolution test.
The f2 values of the formulation ER-F/ER-V and the formula-
tion ER-S/ER-Vwere 76.6 and 40.3, respectively, indicating that
the drug release rate from formulation ER-V was different to
that from the ER-F and ER-S formulations.
j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 2 ( 2 0 1 4 ) 2 5 7e2 6 32623.2. In vivo studies
The plasma concentration profiles of ER dosage formulations
aswell as that of the IR dosage formulation are shown in Fig. 2.
The mean pharmacokinetic parameters, Cmax, Tmax, and
AUC0eN are summarized in Table 2. The AUC0eN and Cmax
values were 1509.12 128.90 ng h/mL and 140.82 23.85 ng/
mL for formulation ER-F and 955.35  159.89 ng  h/mL and
78.83  31.42 ng/mL for formulation ER-S, respectively. It was
found that Tmax values of ER tablets (ER-S and ER-F) were
prolonged when compared with the IR commercial products.
The Tmax values of ER-F and ER-S were not significantly
different. The rank order of Cmax and AUC of ER tablets was
reflected in the drug release rate observed in dissolution test.3.3. The development of the IVIVC model
The in vivo cumulative absorption fraction profiles of pro-
pranolol ER tablets of ER-S and ER-F calculated by the nu-
merical deconvolution analysis are shown in Fig. 3. It was
found that the same rank order was observed between the
in vitro release rate of dissolution (Fig. 1) and the in vivo release
rate of absorption (Fig. 3), i.e., formulation ER-F > formulation
ER-S. The IVIVC model was developed by using the linear
regression based on the “% in vitro cumulative dissolved (t)”
and “% in vivo cumulative input (t)” of formulation ER-F and
ER-S (Fig. 4). The determination coefficient r2 was 0.9555,
indicating a good linear correlation for the IVIVC model
(p < 0.05). The intercept and slope were a ¼ 0.0318 and
b ¼ 0.8517, respectively. The slope of 0.8517 was lower than 1,
indicating that the in vivo absorption rate was under-
estimated. The phenomenon might be attributed to the he-
patic first pass effect of propranolol [10].3.4. Validation of the IVIVC model
The internal validation was accomplished by convolving the
dissolution data corresponding to the formulations ER-S and
ER-F. Fig. 5 shows the observed and predicted plasma con-
centrations for formulation ER-F (Fig. 5A) and formulation ER-S
(Fig. 5B), respectively. Table 3 represents the%PE values for the
Cmax andAUC0eNof these twoER formulations.The%PEvalues
of the Cmax and AUC0eN for formulation ER-S were 36.80% and
23.00%, respectively. The%PE values of the Cmax andAUC0eN
for formulation ER-Fwere 3.45% and4.92%, respectively. The
average absolute %PE values of Cmax and AUC0eN were 13.9%
and 20.1%, respectively. The FDA guidelines [1] state that the
predictability can be accepted when the average absolute %PETable 3 e Percent prediction errors (%PE) associated with
Cmax and AUC0eN.
Formulations Cmax AUC0eN
Internal predictability
ER-F 3.45% 4.92%
ER-S 36.80% 23.00%
Average absolute %PE 20.13% 13.96%
External predictability
ER-V 0.86% 5.95%valuesareof10%or lessand the%PEvalue for each formulation
should not exceed 15%. In the present study, the average ab-
solute%PE values ofAUC0eN andCmax for the formulation ER-F
and ER-S were >10%. The failure of the IVIVCmodel to predict
the extent of propranolol hydrochloride absorption may be
explained by the first-passmetabolism. The in vitro dissolution
data presented the total dose; however, the in vivo absorption
data presented the fraction of the active drug reaching the
systemic circulation. Because the predicted AUC0eN involved
converting the in vitro dissolution profile into the in vivo
dissolution profile, the predicted AUC0eN values of the
formulation ER-F and ER-S might be higher than the observed
AUC0eN values. Thus, if we utilized the in vitro dissolution
profiles topredict the in vivoabsorption,weshouldconsider the
factor of first-pass metabolism. The previous studies have re-
ported that first-pass metabolism played an important role in
the assessment of bioequivalence [15e17]. Sirisuth and
Eddington [10] proved that the influence of the first-pass
metabolism of an IVIVC model on metoprolol ER tablets in
which metoprolol displayed a high extraction ratio, was the
same as for propranolol. Furthermore, Keller et al [18] reported
that the bioavailability of long-acting propranolol decreased
with thedrugabsorption rate (Ka).Hence, thehigh%PEvalueof
theAUC0eNof formulationER-Smaycontribute to thedecrease
of the drug absorption rate.
The FDAguidelines [1] declare that if the criteria for internal
validation are not met, the external predictability should be
evaluated as the final determination of the IVIVCmodel. Then,
the in vitro dissolved rate and in vivo absorbed rate of an addi-
tional ER formulation, ER-V, was used to examine the ability of
the IVIVCmodel and to predict the in vivo performance. Fig. 5C
shows the observed and predicted plasma concentration pro-
files. The %PE values of the Cmax and AUC0eN for formulation
ERMwere0.86%and5.95% (Table3), respectively.Anabsolute
%PE value of 10% or less for Cmax and AUC0eN validated the
external predictability of an IVIVCmodel,which indicated that
the results met the criteria of IVIVC guidelines for good
external predictability [1]. This demonstrates that the IVIVC
model could be used as a surrogate for bioequivalence.4. Conclusions
In this preliminary study, a level A IVIVC model for propran-
olol ER dosage formulations was developed and estimated for
both internal and external predictability. Although the model
was not acceptable for validating internal predictability, vali-
dation of external predictability was achieved. Thus, this
IVIVC model might be used to predict the variation in site
change, process changes, scale-up, and to predict the ab-
sorption performance of propranolol hydrochloride products
with different release rates.r e f e r e n c e s
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